CN106617053A - Healthcare food for preventing and treating prostatitis and prostatic hyperplasia and preparation method thereof - Google Patents
Healthcare food for preventing and treating prostatitis and prostatic hyperplasia and preparation method thereof Download PDFInfo
- Publication number
- CN106617053A CN106617053A CN201611086042.7A CN201611086042A CN106617053A CN 106617053 A CN106617053 A CN 106617053A CN 201611086042 A CN201611086042 A CN 201611086042A CN 106617053 A CN106617053 A CN 106617053A
- Authority
- CN
- China
- Prior art keywords
- parts
- extract
- maca
- prostatitis
- health food
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000007094 prostatitis Diseases 0.000 title claims abstract description 48
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 title claims abstract description 38
- 238000002360 preparation method Methods 0.000 title claims abstract description 27
- 235000013305 food Nutrition 0.000 title abstract description 13
- 208000004403 Prostatic Hyperplasia Diseases 0.000 title abstract 4
- 240000000759 Lepidium meyenii Species 0.000 claims abstract description 46
- 235000000421 Lepidium meyenii Nutrition 0.000 claims abstract description 46
- 235000012902 lepidium meyenii Nutrition 0.000 claims abstract description 46
- 239000003814 drug Substances 0.000 claims abstract description 43
- 240000003915 Lophatherum gracile Species 0.000 claims abstract description 30
- 239000002994 raw material Substances 0.000 claims abstract description 20
- 239000000463 material Substances 0.000 claims abstract description 13
- 239000007902 hard capsule Substances 0.000 claims abstract description 9
- 239000000284 extract Substances 0.000 claims description 59
- 240000007164 Salvia officinalis Species 0.000 claims description 40
- 240000006108 Allium ampeloprasum Species 0.000 claims description 34
- 235000005254 Allium ampeloprasum Nutrition 0.000 claims description 33
- 239000000203 mixture Substances 0.000 claims description 33
- 235000013402 health food Nutrition 0.000 claims description 32
- 235000005412 red sage Nutrition 0.000 claims description 30
- 241001165494 Rhodiola Species 0.000 claims description 29
- 238000000605 extraction Methods 0.000 claims description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 22
- 239000007788 liquid Substances 0.000 claims description 15
- 239000012467 final product Substances 0.000 claims description 14
- 229920001353 Dextrin Polymers 0.000 claims description 10
- 239000004375 Dextrin Substances 0.000 claims description 10
- 235000017276 Salvia Nutrition 0.000 claims description 10
- 229920002472 Starch Polymers 0.000 claims description 10
- 235000019425 dextrin Nutrition 0.000 claims description 10
- 239000008107 starch Substances 0.000 claims description 10
- 235000019698 starch Nutrition 0.000 claims description 10
- 241000234282 Allium Species 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 9
- 238000004806 packaging method and process Methods 0.000 claims description 7
- 239000000080 wetting agent Substances 0.000 claims description 7
- 239000008187 granular material Substances 0.000 claims description 6
- 238000003672 processing method Methods 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 235000020985 whole grains Nutrition 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- CIWBSHSKHKDKBQ-DUZGATOHSA-N D-araboascorbic acid Natural products OC[C@@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-DUZGATOHSA-N 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 4
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 claims description 4
- 235000010350 erythorbic acid Nutrition 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 4
- 239000011777 magnesium Substances 0.000 claims description 4
- 229910052749 magnesium Inorganic materials 0.000 claims description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- DINKXUCRJBUQAZ-UHFFFAOYSA-N tert-butyl 5-bromopyridine-3-carboxylate Chemical compound CC(C)(C)OC(=O)C1=CN=CC(Br)=C1 DINKXUCRJBUQAZ-UHFFFAOYSA-N 0.000 claims description 4
- 239000003643 water by type Substances 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 3
- 238000002481 ethanol extraction Methods 0.000 claims description 3
- 239000000194 fatty acid Substances 0.000 claims description 3
- 229930195729 fatty acid Natural products 0.000 claims description 3
- 150000004665 fatty acids Chemical class 0.000 claims description 3
- 238000003809 water extraction Methods 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 235000021552 granulated sugar Nutrition 0.000 claims description 2
- 235000019359 magnesium stearate Nutrition 0.000 claims description 2
- 235000013339 cereals Nutrition 0.000 claims 1
- 238000005507 spraying Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 24
- 208000013507 chronic prostatitis Diseases 0.000 abstract description 10
- 210000004369 blood Anatomy 0.000 abstract description 7
- 239000008280 blood Substances 0.000 abstract description 7
- 235000006886 Zingiber officinale Nutrition 0.000 abstract description 6
- 235000008397 ginger Nutrition 0.000 abstract description 6
- 210000004185 liver Anatomy 0.000 abstract description 6
- 210000003734 kidney Anatomy 0.000 abstract description 5
- 235000005338 Allium tuberosum Nutrition 0.000 abstract description 3
- 244000003377 Allium tuberosum Species 0.000 abstract description 3
- 235000003713 Rhodiola rosea Nutrition 0.000 abstract description 3
- 244000042430 Rhodiola rosea Species 0.000 abstract description 3
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 abstract description 3
- 238000005516 engineering process Methods 0.000 abstract description 3
- 239000002245 particle Substances 0.000 abstract description 3
- 239000003826 tablet Substances 0.000 abstract description 3
- 230000001976 improved effect Effects 0.000 abstract description 2
- 231100000252 nontoxic Toxicity 0.000 abstract description 2
- 230000003000 nontoxic effect Effects 0.000 abstract description 2
- 230000003014 reinforcing effect Effects 0.000 abstract description 2
- 235000018645 Allium odorum Nutrition 0.000 abstract 2
- 241000304195 Salvia miltiorrhiza Species 0.000 abstract 2
- 244000273928 Zingiber officinale Species 0.000 abstract 2
- 206010051482 Prostatomegaly Diseases 0.000 abstract 1
- 229940100688 oral solution Drugs 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 239000000047 product Substances 0.000 description 48
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 32
- 210000002307 prostate Anatomy 0.000 description 26
- 241000700159 Rattus Species 0.000 description 16
- 229960003604 testosterone Drugs 0.000 description 16
- 238000003304 gavage Methods 0.000 description 12
- 230000036541 health Effects 0.000 description 10
- 239000000469 ethanolic extract Substances 0.000 description 9
- 210000004907 gland Anatomy 0.000 description 9
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 230000027939 micturition Effects 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 7
- 108090001007 Interleukin-8 Proteins 0.000 description 7
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 7
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 7
- 206010020718 hyperplasia Diseases 0.000 description 7
- 229940089536 indocin Drugs 0.000 description 7
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 7
- 208000002193 Pain Diseases 0.000 description 6
- 241000234314 Zingiber Species 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 230000037209 prostate health Effects 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 5
- 235000017491 Bambusa tulda Nutrition 0.000 description 5
- 244000082204 Phyllostachys viridis Species 0.000 description 5
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 5
- 239000011425 bamboo Substances 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 206010069918 Bacterial prostatitis Diseases 0.000 description 4
- -1 Flavone compound Chemical class 0.000 description 4
- 240000004371 Panax ginseng Species 0.000 description 4
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 4
- 235000003140 Panax quinquefolius Nutrition 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 230000000975 bioactive effect Effects 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 229930003944 flavone Natural products 0.000 description 4
- 235000011949 flavones Nutrition 0.000 description 4
- 235000008434 ginseng Nutrition 0.000 description 4
- 230000008595 infiltration Effects 0.000 description 4
- 238000001764 infiltration Methods 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 3
- 102000003777 Interleukin-1 beta Human genes 0.000 description 3
- 108090000193 Interleukin-1 beta Proteins 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- 102000004890 Interleukin-8 Human genes 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N Tanshinone I Chemical compound C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 230000002929 anti-fatigue Effects 0.000 description 3
- 238000005253 cladding Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000035619 diuresis Effects 0.000 description 3
- 210000000981 epithelium Anatomy 0.000 description 3
- 210000004969 inflammatory cell Anatomy 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 210000003127 knee Anatomy 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 241000219193 Brassicaceae Species 0.000 description 2
- GVKKJJOMQCNPGB-JTQLQIEISA-N Cryptotanshinone Chemical compound O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1[C@@H](C)CO2 GVKKJJOMQCNPGB-JTQLQIEISA-N 0.000 description 2
- GVKKJJOMQCNPGB-UHFFFAOYSA-N Cryptotanshinone Natural products O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1C(C)CO2 GVKKJJOMQCNPGB-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 241000801118 Lepidium Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010059013 Nocturnal emission Diseases 0.000 description 2
- 208000025844 Prostatic disease Diseases 0.000 description 2
- 241000219780 Pueraria Species 0.000 description 2
- 240000005319 Sedum acre Species 0.000 description 2
- 235000014327 Sedum acre Nutrition 0.000 description 2
- DRHKJLXJIQTDTD-OAHLLOKOSA-N Tamsulosine Chemical compound CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1 DRHKJLXJIQTDTD-OAHLLOKOSA-N 0.000 description 2
- 229930183118 Tanshinone Natural products 0.000 description 2
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 2
- 239000003098 androgen Substances 0.000 description 2
- 230000001548 androgenic effect Effects 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000003035 anti-peroxidant effect Effects 0.000 description 2
- 210000002469 basement membrane Anatomy 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000000496 cardiotonic agent Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 150000002213 flavones Chemical class 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000036299 sexual function Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 229960002613 tamsulosin Drugs 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 2
- YVWMHFYOIJMUMN-CYZWUHAYSA-N (6e,8e)-5-oxooctadeca-6,8-dienoic acid Chemical compound CCCCCCCCC\C=C\C=C\C(=O)CCCC(O)=O YVWMHFYOIJMUMN-CYZWUHAYSA-N 0.000 description 1
- 241000427159 Achyranthes Species 0.000 description 1
- 241000173529 Aconitum napellus Species 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 241000554155 Andes Species 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 235000008671 Calycanthus floridus Nutrition 0.000 description 1
- 244000025311 Calycanthus occidentalis Species 0.000 description 1
- 235000008670 Calycanthus occidentalis Nutrition 0.000 description 1
- 241000131329 Carabidae Species 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 1
- 244000020518 Carthamus tinctorius Species 0.000 description 1
- 241000005787 Cistanche Species 0.000 description 1
- 235000003392 Curcuma domestica Nutrition 0.000 description 1
- 244000008991 Curcuma longa Species 0.000 description 1
- 235000003405 Curcuma zedoaria Nutrition 0.000 description 1
- 240000009138 Curcuma zedoaria Species 0.000 description 1
- 241000522190 Desmodium Species 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- 241001016310 Epimedium grandiflorum Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 244000111489 Gardenia augusta Species 0.000 description 1
- 235000018958 Gardenia augusta Nutrition 0.000 description 1
- 241000545744 Hirudinea Species 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 235000004520 Lindera benzoin Nutrition 0.000 description 1
- 235000008262 Lindera benzoin var. benzoin Nutrition 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 241000361919 Metaphire sieboldi Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 235000019082 Osmanthus Nutrition 0.000 description 1
- 241000333181 Osmanthus Species 0.000 description 1
- 208000031816 Pathologic Dilatation Diseases 0.000 description 1
- 208000000450 Pelvic Pain Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 240000002014 Phyllostachys nigra var. henonis Species 0.000 description 1
- 235000006386 Polygonum aviculare Nutrition 0.000 description 1
- 244000292697 Polygonum aviculare Species 0.000 description 1
- 241000241413 Propolis Species 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 206010064022 Prostatic mass Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 241000736246 Pyrola Species 0.000 description 1
- 244000088415 Raphanus sativus Species 0.000 description 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- PDMMFKSKQVNJMI-BLQWBTBKSA-N Testosterone propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 PDMMFKSKQVNJMI-BLQWBTBKSA-N 0.000 description 1
- 241001078983 Tetradium ruticarpum Species 0.000 description 1
- 235000008214 Thlaspi arvense Nutrition 0.000 description 1
- 240000008488 Thlaspi arvense Species 0.000 description 1
- 235000001484 Trigonella foenum graecum Nutrition 0.000 description 1
- 244000250129 Trigonella foenum graecum Species 0.000 description 1
- 240000000920 Typhonium flagelliforme Species 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 235000003373 curcuma longa Nutrition 0.000 description 1
- 239000001812 curcuma zedoaria berg. rosc. Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 235000018905 epimedium Nutrition 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000009313 farming Methods 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000004383 glucosinolate group Chemical group 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229940087603 grape seed extract Drugs 0.000 description 1
- 235000002532 grape seed extract Nutrition 0.000 description 1
- 229940094952 green tea extract Drugs 0.000 description 1
- 235000020688 green tea extract Nutrition 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 239000000568 immunological adjuvant Substances 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 229930195208 isotanshinone Natural products 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 201000005630 leukorrhea Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229940069949 propolis Drugs 0.000 description 1
- 244000132619 red sage Species 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 239000003507 refrigerant Substances 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 210000004706 scrotum Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229960001712 testosterone propionate Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 235000001019 trigonella foenum-graecum Nutrition 0.000 description 1
- 235000013976 turmeric Nutrition 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 206010046901 vaginal discharge Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000001717 vitis vinifera seed extract Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 235000019509 white turmeric Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/41—Crassulaceae (Stonecrop family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a healthcare food for preventing and treating prostatitis and prostatic hyperplasia and a preparation method thereof. The healthcare food comprises the following raw materials in parts by weight: 20 to 40 parts of lophatherum gracile, 15 to 30 parts of maca, 10 to 20 parts of dried ginger, 5 to 15 parts of salvia miltiorrhiza, 5 to 15 parts of rhodiola rosea and 5 to 10 parts of Chinese chive seeds. Biological healthcare active molecules are extracted through a modern traditional Chinese medicine technology; edible auxiliary materials are added into the extracted biological healthcare active molecules to prepare tablets, particles, hard capsules or an oral solution. The biological utilization degree of the biological healthcare active molecules of the lophatherum gracile, the maca, the dried ginger, the salvia miltiorrhiza, the rhodiola rosea and the Chinese chive seeds is improved through a bionanotechnology; the healthcare food for preventing and treating the prostatitis is prepared through fine processing; the healthcare food for preventing and treating the prostatitis and the prostatic hyperplasia prepared by the formula disclosed by the invention is safe and effective to eat and is non-toxic and harmless, has the effects of nourishing yin and blood, regulating and tonifying the liver and the kidney, dredging collaterals and reinforcing yang, and has a good preventing and treating effect on the prostatitis, chronic prostatitis, prostatomegaly, prostatic hyperplasia and the like.
Description
Technical field
The present invention relates to a kind of health food and preparation method for preventing and treating prostatitis and hyperplasia of prostate, and in particular to one
Plant by the male sex's special health food being formulated as raw material with lophatherum gracile, maca, rhizoma zingiberis, the red sage root, rhodiola root and leek seed
Formula and preparation method, belong to man's health food technical field.
Background technology
Male sex's common disease in prostatitis and hyperplasia of prostate.Prostatitis is the prostate that Various Complex reason causes
Inflammation, causes the disease with urethral stimulant symptom and chronic pelvic pain as main clinical manifestation.Row gland hyperplasia is wrapping urine portion
Prostatic cell adenomatous hyperplasia, be common disease, the frequently-occurring disease of middle Laonan's property.Its symptom is mainly because of the blocking of hyperplasia prostate
The obstructive symptoms that urinary tract is produced：Frequent micturition, number of micturitions increase, can not bear urine urgent urination, start delay, the urinary incontinence, night during urination
Frequent micturition is numerous, incomplete sensation of urinating, urination interruption, odynuria.Prostatitis and hyperplasia of prostate have a strong impact on minimal invasive treatment's matter
Amount, to patient body health serious harm is caused.
Lophatherum gracile (Lophatherum gracile) is herbaceos perennial, there is refrigerant, antipyretic, diuresis and hastens parturition it
Effect；Indication：Clearing heat and relieving fidgetness, diuresis.Pain, aphthae are drenched for pyreticosis polydipsia, hot urination.Containing substantial amounts of in the leaf of bamboo
Flavone compound and bioactive polysaccharide and other active ingredients, bamboo extractive have excellent Green Tea Extract, it is anti-oxidant,
The effect of anti-aging, reducing blood lipid and cholesterolemia.Herba Lophatheri extract main component bamboo-leaves flavones, are approved as new resources in 2014
Food (bulletin (2014 No. 20) with regard to ratifying 9 kinds of new raw-food materials such as tomato seed oil)
Maca, makees agate card (Maca, Lepidium meyemii Walp) again, and category Cruciferae (Cruciferae) is walked alone
The root tuber class of Lepidium likeness in form radish is annual or biennial herbaceous plant, originates in the south of Peru's 3500～4500 meters of height above sea level in middle part
U.S. andes region, locals is mainly used in as food, can use as conventional medicament, is natural food.Contain in maca
There is the nutrition such as macamide (macamides), maca ene (macaenes), glucosinolate, sterol, steroids work composition, to man
Property prostate there is health-care efficacy, pueraria root powder is approved as new resource food for 2011 and (eats as new resources with regard to ratifying pueraria root powder
The bulletin (2011 No. 13) of product).Maca has antifatigue, anti-aging, adjusts internal system, improve sexual function, improve
The effects such as fecundity, reduction hyperplasia of prostate.
Rhizoma zingiberis, is the dry rhizome of zingiber (Zingiber oj-jicinale Rosc.).《Legendary god of farming's book on Chinese herbal medicine
Jing》Middle product are classified as,《Mingyi Bielu》It is classified as middle product.Taste is pungent, property heat.Returns spleen, stomach, the heart, lung channel.There are warming spleen and stomach for dispelling cold, Hui Yangtong
Arteries and veins, eliminating dampness dissolving phlegm, Wenfei of drink effect.Treat with Central nervous, cardiovascular system, digestive system, anti-inflammatory, antitumor etc.
Effect, with androgen biologically active, can be used to prevent and treat the effect of male prostate relevant disease.
The red sage root, is the dry root and rhizome of the labiate red sage root (Salvia miltiorrhiza Bge.).Bitter, it is micro-
It is cold.The thoughts of returning home, Liver Channel.It is inducing meastruation to relieve menalgia with promoting blood circulation, relieving restlessness that clears away heart-fire, the effect of cool blood to disappear carbuncle.For chest impediment and cardialgia, gastral cavity abdomen
Hypochondriac pain, the accumulation of lump in the abdomen lump in the abdomen, hot numbness pain, dysphoria and insomnia, irregular menstruation, dysmenorrhoea Amenorrhea, sore swell and ache curative etc..Contain tanshinone in the red sage root
Ith, II A, II B, Cryptotanshinone, isotanshinone, the tanshinone compound such as different Cryptotanshinone, with stronger androgenic effect,
Can be used to prevent and treat the effect of male prostatitis and prostate cancer.
Rhodiola root (Rhodiola rosea L.), is herbaceos perennial, is grown in height above sea level 1800-2500 rice high and cold
Contamination-freely band, its growing environment is severe, thus with very strong vitality and special adaptability.With tonifying Qi clearing lung-heat, benefit
Intelligence nourishing heart effect, with CNS inhibition, antifatigue, cardiac stimulant, anti-inflammatory, blood glucose rise processed, anti-peroxidation and male prostate health care
Deng effect.
Leek seed is the dry mature seed of liliaceous plant leek (Allium tuberosum Rottler), and property is pungent,
Sweet, temperature returns kidney, Liver Channel, semen allii tuberosi to have warm filling liver kidney, and establishing-Yang controlling nocturnal emission with astringent drugs warms up effect of waist and knee, and leek seed controls impotence, seminal emission, leukorrhea
White excessive, the enuresis, frequent urination, soreness and weakness of waist and knees, crymodynia.
A kind of compound Chinese medicinal preparation (Chinese patent CN 103393773) report for treating hyperplasia of prostate is using monkshood, meat
Osmanthus, the root of three-nerved spicebush, leech, ground beetle, the compound Chinese medicinal preparation that earthworm is raw material preparation.A kind of health food for preventing and treating prostatic disorders and
Preparation method (Chinese patent CN 101019986) report using Typhonium flagelliforme (Lodd.) Blume, evodia rutaecarpa, the root of bidentate achyranthes, saline cistanche, barrenwort, the red sage root,
The health food of prostatic disorders is prevented and treated made by fenugreek, pyrola, Allium tuberasum.seeds, grape seed extract, propolis etc..One
Kind for prostate health products (Chinese patent CN CN102335393) report using field pennycress, desmodium, cape jasmine total saposins,
Safflower flavone, oil of zedoary turmeric, peppermint oil etc. are raw material, prepare the health products of prostate.So far there are no with lophatherum gracile, maca, rhizoma zingiberis,
The report for preventing and treating prostatitis and hyperplasia of prostate and answer that the red sage root, rhodiola root and leek seed are formulated for raw material
With.
The content of the invention
Purpose：To solve the deficiencies in the prior art, the present invention provides a kind of guarantor for preventing and treating prostatitis and hyperplasia of prostate
Health food and preparation method, with the addition of functional health food replenishers so that lophatherum gracile, maca, rhizoma zingiberis, the red sage root, rhodiola root
Good Deng the bioactive molecule bioavilability in raw material, effective molecular melting is fast.
Technical scheme：To solve above-mentioned technical problem, the technical solution used in the present invention is：
A kind of health food for preventing and treating prostatitis and hyperplasia of prostate, it is characterised in that including following parts by weight
Raw material：Lophatherum gracile 20-40 parts, maca 15-30 part, rhizoma zingiberis 10-20 parts, red sage root 5-15 parts, rhodiola root 5-15 parts, leek seed 5-10
Part.
The processing method of raw material is as follows：Above-mentioned raw materials are proportionally respectively processed, are cleaned, dried or dry, powder
It is broken, you can；Or further with alcohol extracting or water extraction extraction；Lophatherum gracile, maca, rhizoma zingiberis, the red sage root are respectively adopted ethanol extraction, institute
It is spray-dried to obtain Herba Lophatheri extract, Maca extract, Rhizoma Zingiberis extract and Salvia root P.E after obtaining extract concentration；It is red
Red-spotted stonecrop and leek seed are extracted using water, spray-dried to obtain gadol extract and leek seed extraction after the concentration of gained extract
Thing.
The processing method of raw material is as follows：Above-mentioned raw materials are proportionally respectively processed, lophatherum gracile, maca, rhizoma zingiberis, pellet
Ginseng, rhodiola root and leek seed extracted respectively, concentrated, be dried after Herba Lophatheri extract, Maca extract, rhizoma zingiberis are extracted
Thing, Salvia root P.E, gadol extract and Allium tubersum rottl extract, are then sufficiently mixed them uniformly, obtain final product traditional Chinese medicine extraction
Composition.
A kind of described health food for preventing and treating prostatitis and hyperplasia of prostate, it is characterised in that：The health food
Formulation be tablet, granule, hard capsule or oral liquid.
The preparation method of tablet is as follows：Traditional Chinese medicine extraction composition 30-60 parts, add starch 20-40 parts, carboxymethylcellulose calcium
5-10 parts, dextrin 5-10 parts, mixing 20-40 minutes in input mixer, add ethanol as wetting agent, mix 10-20 minutes,
Mixed material is pelletized with 10-20 mesh sieves, is put in drying equipment and is dried, the magnesium stearate of addition 1-5 parts, whole grain, compressing tablet,
Packaging, obtains final product.
The preparation method of granule is as follows：Traditional Chinese medicine extraction composition 30-70 parts, add starch 10-25 parts, dextrin 10-30
Part, white granulated sugar 5-10 parts, add ethanol as wetting agent at mixing 20-40 minutes in input mixer, mix 10-20 minutes, mix
Material after conjunction is pelletized with 10-20 mesh sieves, is put in drying equipment and is dried, and dry particle is sieved with 20-60 eye mesh screens, is removed thick
Particle and fine powder, packaging, obtain final product.
The preparation method of hard capsule is as follows：Traditional Chinese medicine extraction composition 10-50 parts, starch 40-70 parts, dextrin 5-10 parts,
Mixing 20-30 minutes in input mixer, add ethanol as wetting agent, mix 10-20 minutes, mixed material 10-
20 mesh sieves are pelletized, and add the hard fatty acids magnesium of 1-5 parts, whole grain, capsule charge, packaging to obtain final product.
The preparation method of oral liquid is as follows：1 part of traditional Chinese medicine extraction composition, adds 4-40 part purified waters to be well mixed orally
Liquid, adds appropriate D-araboascorbic acid sodium, filters, dispenses, sterilizes, packs, and obtains final product.
Beneficial effect：A kind of health food and preparation side for preventing and treating prostatitis and hyperplasia of prostate that the present invention is provided
Method, using differential diagnosis in tcm discuss Overall View, by lophatherum gracile, maca, rhizoma zingiberis, the red sage root, rhodiola root and leek seed to prostate
Relevant disease has preventing and treating health-care efficacy bioactive molecule to be developed into male sex's special health food, makes it have more section on health-care efficacy
The property learned, validity, targeting；The health-care efficacy of the combination is in addition to respective efficacy exertion, and its is specific with when production technology,
With nourishing yin and nourishing blood, adjusting and reinforcing liver and kidney, effect that dredging collateral is supporing yang, can be used to treat prostatitis, chronic prostatitis, prostate fertilizer
Big and hyperplasia of prostate etc..Lophatherum gracile can obtain the health product raw material based on bamboo-leaves flavones by alcohol extracting, can heat-clearing, diuresis, use
In treatment prostatitis top grade.Maca has abundant nutritive value and health-care efficacy, in dispelling fatigue, adjust endocrine, subtracts
The relevant disease that the decline of young boy's property prostatic function causes has preventive and therapeutic effect.Rhizoma zingiberis has stronger androgen biologically active,
There is anti-inflammatory curative effect to cardiovascular, digestion and urinary system, there is preventing and treating health-care efficacy to male prostatitis and hyperplasia.The red sage root
With promoting blood circulation and internal system is adjusted, with stronger androgenic activity, can be used to prevent and treat male prostatitis and front
The effect of row gland cancer.Rhodiola root has before CNS inhibition, antifatigue, cardiac stimulant, anti-inflammatory, blood glucose rise processed, anti-peroxidation and the male sex
Row gland health care etc. is acted on.Leek seed has warm filling liver kidney, and establishing-Yang controlling nocturnal emission with astringent drugs warms up effect of waist and knee.Lophatherum gracile, maca, rhizoma zingiberis, pellet
Ginseng, rhodiola root and leek seed improve biological health bioactive molecule bioavilability by bio-nanotechnology, by finishing system
It is standby into preventing and treating prostatitis and hyperplasia of prostate health food.Edible safety of the present invention is effectively, nontoxic.For prostate
Inflammation, chronic prostatitis, hypertrophy of the prostate and hyperplasia of prostate etc. have good curative effect of preventing and treating to improve sexual function, are improving body
Immunologic function has synergism.
Treatment zoopery of the present invention and clinical research, zoopery：The determination of activity of chronic prostate adenositis
Using method be intervene autoimmune prostatitis rat model, detect prostata tissue pathomorphism and inflammation water
It is flat.Clinical research is suffered from using male health-care product (preventing and treating prostatitis and hyperplasia of prostate health food) treatment chronic prostatitis
Person 80, observes clinical efficacy.
Specific embodiment
The present invention is illustrated with reference to embodiment：
One kind prevents and treats prostatitis and hyperplasia of prostate health food, it is characterised in that including the original of following parts by weight
Material：Lophatherum gracile 20-40 parts, maca 15-30 part, rhizoma zingiberis 10-20 parts, red sage root 5-15 parts, rhodiola root 5-15 parts, leek seed 5-10
Part.
Above-mentioned raw materials are proportionally respectively processed, are cleaned, dried or dry, crushed, you can；
Or further with alcohol extracting or water extraction extraction；Lophatherum gracile, maca, rhizoma zingiberis, the red sage root are respectively adopted ethanol extraction, institute
It is spray-dried to obtain Herba Lophatheri extract, Maca extract, Rhizoma Zingiberis extract and Salvia root P.E after obtaining extract concentration；It is red
Red-spotted stonecrop and leek seed are extracted using water and extracted using water, after the concentration of gained extract, spray-dried gadol extract and
Allium tubersum rottl extract.
When specifically used, lophatherum gracile, maca, rhizoma zingiberis, the red sage root, rhodiola root and leek seed can be all active compound materials,
Can also all extracts composition, extract be with crude drug extract and obtain.
Preferably, the processing method of raw material is as follows：Above-mentioned raw materials are proportionally respectively processed, henon bamboo
Leaf, maca, rhizoma zingiberis, the red sage root, rhodiola root and leek seed extracted respectively, concentrated, be dried after Herba Lophatheri extract, maca are carried
Thing, Rhizoma Zingiberis extract, Salvia root P.E, gadol extract and Allium tubersum rottl extract are taken, then fully mixes these extracts
Close uniform, obtain final product traditional Chinese medicine extraction composition.
The formulation of the health food for preventing and treating prostatitis and hyperplasia of prostate be tablet, granule, hard capsule or
Oral liquid.
Embodiment 1 (is below parts by weight)
Lophatherum gracile, maca, rhizoma zingiberis, the red sage root, rhodiola root and leek seed parts by weight are：It is 40 parts of lophatherum gracile, 15 parts of maca, dry
20 parts of ginger, 5 parts of the red sage root, 15 parts of rhodiola root, 10 parts of leek seed, cleaning, dry or dry, and crush, and Chinese medicine are obtained after being well mixed former
Material mixture 1.
Embodiment 2
Lophatherum gracile, maca, rhizoma zingiberis, the red sage root, rhodiola root and leek seed parts by weight are：It is 20 parts of lophatherum gracile, 35 parts of maca, dry
10 parts of ginger, 15 parts of the red sage root, 10 parts of rhodiola root, 10 parts of leek seed；Proportionally be respectively processed, lophatherum gracile, maca, rhizoma zingiberis,
The red sage root, rhodiola root and leek seed extracted respectively, concentrated, be dried after Herba Lophatheri extract, Maca extract, rhizoma zingiberis are extracted
Thing, Salvia root P.E, gadol extract and Allium tubersum rottl extract, are then sufficiently mixed these extracts uniformly, obtain final product light
The traditional Chinese medicine extraction composition 2 of the leaf of bamboo, maca, rhizoma zingiberis, the red sage root, rhodiola root and leek seed.
Embodiment 3
Lophatherum gracile, maca, rhizoma zingiberis, the red sage root, rhodiola root and leek seed parts by weight are：It is 40 parts of lophatherum gracile, 25 parts of maca, dry
10 parts of ginger, 10 parts of the red sage root, 5 parts of rhodiola root, 10 parts of leek seed；Proportionally it is respectively processed, lophatherum gracile, maca, rhizoma zingiberis, pellet
Ginseng, rhodiola root and leek seed extracted respectively, concentrated, be dried after Herba Lophatheri extract, Maca extract, rhizoma zingiberis are extracted
Thing, Salvia root P.E, gadol extract and Allium tubersum rottl extract, are then sufficiently mixed these extracts uniformly, obtain final product light
The traditional Chinese medicine extraction composition 3 of the leaf of bamboo, maca, rhizoma zingiberis, the red sage root, rhodiola root and leek seed.
Embodiment 4
Lophatherum gracile, maca, rhizoma zingiberis, the red sage root, rhodiola root and leek seed parts by weight are：It is 30 parts of lophatherum gracile, 30 parts of maca, dry
20 parts of ginger, 15 parts of the red sage root, 5 parts of rhodiola root, 5 parts of leek seed；Proportionally it is respectively processed, lophatherum gracile, maca, rhizoma zingiberis, pellet
Ginseng, rhodiola root and leek seed extracted respectively, concentrated, be dried after Herba Lophatheri extract, Maca extract, rhizoma zingiberis are extracted
Thing, Salvia root P.E, gadol extract and Allium tubersum rottl extract, are then sufficiently mixed these extracts uniformly, obtain final product light
The traditional Chinese medicine extraction composition 4 of the leaf of bamboo, maca, rhizoma zingiberis, the red sage root, rhodiola root and leek seed.
Embodiment 2 is to embodiment 4：
The preparation of EXPERIMENTAL EXAMPLE 2 to traditional Chinese medicinal components in embodiment 4 is carried out by the Feedstock Component content specified in table 1 below
Method, respectively obtains the traditional Chinese medicine extraction composition 2 of different component content to traditional Chinese medicine extraction composition 4.
Table 1
Embodiment 5
Prevent and treat the preparation of the health caring food tablet of prostatitis and hyperplasia of prostate：60 parts of traditional Chinese medicine extraction compositions 2, add
30 parts of starch, 5 parts of carboxymethylcellulose calcium, 5 parts of dextrin, add ethanol as moistening at mixing 20-40 minutes in input mixer
Agent, mixes 10-20 minutes, and mixed material is pelletized with 10-20 mesh sieves, is put in drying equipment and is dried, and adds 1 part of tristearin
Sour magnesium, whole grain, compressing tablet, packaging make the tablet of the present invention.
Embodiment 6
Prevent and treat the preparation of the health caring food tablet of prostatitis and hyperplasia of prostate：20 parts of traditional Chinese medicine extraction compositions 3, add
50 parts of starch, 15 parts of carboxymethylcellulose calcium, 15 parts of dextrin, following steps are with example 4.
Embodiment 7
Prevent and treat the preparation of the health food hard capsule of prostatitis and hyperplasia of prostate：50 parts of traditional Chinese medicine extraction compositions 4,
45 parts of starch, 5 parts of dextrin, adds ethanol as wetting agent at mixing 20-40 minutes in input mixer, mixes 10-20 minutes,
Mixed material is pelletized with 10-20 mesh sieves, adds 1 part of hard fatty acids magnesium, whole grain, capsule charge, packaging to make this
Bright hard capsule.
Embodiment 8
Prevent and treat the preparation of the health food hard capsule of prostatitis and hyperplasia of prostate：
15 parts of traditional Chinese medicine extraction compositions 2,75 parts of starch, 10 parts of dextrin, following steps are with example 6.
Embodiment 9
Prevent and treat the preparation of the health-care food oral liquid of prostatitis and hyperplasia of prostate：1 part of traditional Chinese medicine extraction composition 3, plus
Enter 4 parts of purified waters and obtain oral liquid, add appropriate D-araboascorbic acid sodium, filter, dispense, sterilize, pack, that is, make the present invention
Oral liquid.
Embodiment 10
Prevent and treat the preparation of the health-care food oral liquid of prostatitis and hyperplasia of prostate：1 part of traditional Chinese medicine extraction composition 2, plus
Enter 20 parts of purified waters and obtain oral liquid, add appropriate D-araboascorbic acid sodium, following steps are with example 8.
The male health-care product of embodiment 11 are to prostatitis zoopery
Male Wistar big white mouse 40, be randomly divided into model group, Western medicine (indocin) control group, male health-care product group,
Normal group.Totally 30 bacterial prostatitis rat mould is made in addition to normal group only with the method for Escherichia coli injection of prostate
Type.Male health-care product (preventing and treating the health food of prostatitis and hyperplasia of prostate) small dose group gavage male health-care product are suspended
Liquid, 3ml/d (0.5g/ml containing crude drug amount), western medicine group gavage indocin solution 3ml/d (content of dispersion 0.4mg/ml) model
Group, Normal group gavage physiological saline.Gavage is put to death after 30 days, is separated prostata tissue and is weighed parallel pathologic finding；Take neck
Arterial blood extracting 2ml, separates serum, and 4 DEG C save backup detection TNF-α, IL-8.
Table 1：Model rat prostate weight in wet base mean value after the treatment of male health-care product group
Note：Compare with model group, * P<0.05, * * P<0.01；Compare with western medicine group, △ P<0.05.
Model prostatitis rat cellular infiltration situation after the treatment of the male health-care product group of table 2
| Group | n | Cell infiltration (example) | P values |
| Normal group | 10×5 | 2**△ | <0.01 |
| Model group | 10×5 | 48 | |
| Western medicine group | 10×5 | 17** | |
| Health products group | 10×5 | 5**△ | <0.01 |
Note：Compare with model group, * P<0.05, * * P<0.01；Compare with western medicine group, △ P<0.05.
Model rat blood serum TNF-α, IL-8 contents after the treatment of the male health-care product group of table 3
| Group | n | TNF-α(μg/L) | IL-8(ng/L) |
| Normal group | 10 | 162.8±44.25**△ | 17.6±6.2** |
| Model group | 10 | 486.6±191.4 | 49.3±29.8 |
| Western medicine group | 10 | 302.8±196.3* | 29.4±11.2* |
| Health products group | 10 | 193.2±49.7*△ | 18.2±7.1*△ |
Note：Compare with model group, * P<0.05, * * P<0.01；Compare with western medicine group, △ P<0.05.
Treat from table 1 to the visible male health-care product of the result of table 3 (preventing and treating the health food of prostatitis and hyperplasia of prostate)
The prostate gland weight caused by the prostatitis of bacterial prostatitis model rat can be suppressed afterwards to increase, reduce prostate
The inflammatory cell infiltration of acinus and interstitial, reduces proof factor TNF-α, the secretion level of IL-8 in prostata tissue, treatment
Effect is better than Western medicine indocin.
Embodiment 12
Male health-care product (preventing and treating the health food of prostatitis and hyperplasia of prostate) are to chronic non-bacterial prostatitis
The therapeutic action of rat model：56 healthy male Wistar rats, 8 are served only for the preparation of rat prostate protein purification liquid,
Remaining 48 are randomly divided into male health-care product group, Western medicine (indocin) control group, model group, totally 4 groups of Normal group.Except normal
Outside control group, being aided with immunologic adjuvant using rat prostate protein purification liquid, to prepare experimental chronic non-bacterial prostatitis big
Normal group, model group use physiological saline, male health-care product to be configured to suspension and continuously fill when mouse model, modeling 60 days
Stomach, 3ml/d (0.5g/ml containing crude drug amount), Western medicine group gives indocin gavage, 3ml/d (content of dispersion 0.4mg/ml).Each group is administered
Put to death when 14 days, Testing index includes pathology, ELISA method detection prostata tissue homogenate TNF-α, IL-1 β, IL-6, IL-8
Level.
Pathology results show that model group adenomatosis is arranged in cladding and false cladding, and epithelial cell level increases,
Tissue integrity is destroyed, and substantially, interstitial thin vessels expansion, capillary has hemostasis to expand, body of gland quantity for proliferation of fibrous tissue
Increase, the uneven hyperplasia of lumen of gland cell, part galandular epithelium is dashed forward to tube chamber, body of gland ductal ectasia, basement membrane destruction in mamillary, it is seen that
Inflammatory cell infiltrates in acinus and interstitial, has connective tissue proliferation around the body of gland of part；Western medicine (indocin) control group basement membrane
Substantially it is complete, there is a part adenomatosis, the uneven hyperplasia of part lumen of gland cell, in multilayer structure, minority galandular epithelium is in multiple
Layer and false cladding are arranged and form mamillary and dash forward to tube chamber, there is a small amount of inflammatory cell infiltration；Male health-care Pin Zu mirrors undertissue ties
Structure is more complete, and most galandular epitheliums are arranged in individual layer high column, and a small amount of lumen of gland cell is in slight hyperplasia.
Model rat prostate homogenate TNF-α, IL-1 β, IL-8, IL-6 contents after the treatment of the male health-care product of table 4
Note：Compare with Normal group, * P ＜ 0.05, * * P ＜ 0.01；Compare with model group, △ P ＜ 0.05, △ △ P ＜
0.01；Compare with Gentrin Knotweed P.E group, ▲ P ＜ 0.01
The result of table 4 understands, Jing after treatment, western medicine group TNF-α, IL-1 β, IL-8 level are reduced, but IL-6 and model
Group compares reduction not substantially, not statistically significant.Male health-care product substantially reduce inflammatory factor level, with model group comparing difference
It is statistically significant, reduce each inflammatory factor horizon effect and be better than western medicine group.
As a result show, the good therapeutic action that the application of male health-care product has to chronic prostatitis, it is possible to decrease scorching
The disease extent of reaction, so as to promote the effect of prostata tissue structure repair, and effect is better than indocin.
Embodiment 13
Male health-care product treat 80 clinical observations of patients with chronic prostatitis：By 160 patients with chronic prostatitis with
Machine is divided into two groups, and treatment group 80 is treated with male health-care product, and 1.5g/ time oral, and 2 times a day；Control group 80 gives Tan Suoluo
Pungent spansule treatment, each 0.2mg, one time a day.Observation 1 month.Observation index includes clinical efficacy, chronic prostatitis
Symptom integral index (NIH-CPSI).
The male health-care product of table 5 treat the Clinical efficacy comparison (example) of chronic prostatitis
Note：Compare with control group, * P<0.01.
The NIH-CPSI scorings of the male health-care product of table 6 treatment chronic prostatitis are compared
Note：Compare with before treatment, * P ＜ 0.05, * * P ＜ 0.01；Compare with control group, △ △ P ＜ 0.01.
According to table 5, the result of table 6, two groups of Clinical efficacy comparisons, treatment group's curative effect is better than control group, and difference has statistics to anticipate
Justice；Compare with before treatment, two groups of pain, urinate symptom, quality of life and overall score are obviously improved, after treatment group's treatment
NIH-CPSI scorings are substantially less than control group, and difference is statistically significant.The total effective rate of male health-care product, total effective rate are obvious
Better than control group Tamsulosin spansule, pain is uncomfortable in NIH-CPSI, urinate symptom, the scoring of quality of life and overall score
Be decreased obviously, less than control Tamsulosin spansule group, illustrate male health-care product can pain of alleviation, improve urinate and improve
The scoring of quality of life.
The treatment hyperplasia of prostate experiment of the male health-care product of embodiment 14
Animal used as test and its packet：Wistar male rats 56,285 ± 27g of body weight, be randomly divided into Normal group,
Model group, testosterone enanthatas group, testosterone enanthatas and male health-care product low dose group (low dose group), testosterone enanthatas and male health-care product
Middle dose group (middle dose group), testosterone enanthatas and male health-care product high dose group (high dose group), male health-care product ethanol are extracted
Thing.In addition to Normal group, remaining six groups of rat, skin of sterilizing after etherization, Jing scrotum extracts bilateral testes, stump ligation
Hemostasis, skin suture, every rat general muscle injects the u/3d of penicillin 200,000, after performing the operation one week, in addition to Normal group, its
Remaining six groups of rat skin lower injection testosterone propionate 5mg/kg.d, Normal group injection equivalent sesame oil, while injection, enanthic acid testis
Ketone group testosterone enanthatas 0.5mg/kg.d gavages, testosterone enanthatas and male health-care product low dose group testosterone enanthatas 0.1mg/kg.d
With male health-care product ethanol extract 10mg/kg.d gavages, testosterone enanthatas and male health-care product ethanol extract middle dose group use
Testosterone enanthatas 0.25mg/kg.d and male health-care product ethanol extract 20mg/kg.d gavages, testosterone enanthatas and male health-care product second
Alcohol extracting thing high dose group testosterone enanthatas 0.5mg/kg.d and male health-care product ethanol extract 40mg/kg.d gavages, the male sex
Health products ethanol extract group male health-care product ethanol extract 40mg/kg.d gavages, Normal group and model group use etc.
The distilled water gavage of amount.After continuous injection and gavage 28g days, put to death animal and take prostata tissue, weigh, drainage surveys body
Product, calculates prostate coefficient, prostate coefficient=prostatic mass/body weight * 100；Calculate hyperplasia of prostate inhibiting rate (%), suppression
Rate (%) processed=[1- (the normal group coefficient of administration group coefficient one) ÷ (the normal group coefficient of model group coefficient one)] * 100%.All realities
Data are tested to represent, SPSS17.0 softwares carry out one-way analysis of variance process.
Experimental result
Above-mentioned experimental result is as shown in table 1.Compare with model group, the body of prostate of testosterone enanthatas group and extract group rat
The increase of product and prostate index, there is the trend of reduction, and hyperplasia of prostate inhibiting rate is respectively 12.5% and 23.1%, but has no
There is obvious significant difference (p ＞ 0.05)；Compare with model group, the prostate volume and prostate index of low dose group rat
Increase, have the trend of reduction, hyperplasia of prostate inhibiting rate has reached 45.6%, there is significant significant difference (p ＜ 0.05),
And the increase of the prostate volume and prostate index of middle dose group and high dose group rat, reduction trend becomes apparent from, two groups
Hyperplasia of prostate inhibiting rate be respectively 52.3% and 57.2%, significant difference highly significant (p ＜ 0.01), wherein high dose
The testosterone enanthatas and the consumption of male health-care product ethanol extract of group and the testosterone enanthatas consumption of testosterone enanthatas group and male health-care
The male health-care product ethanol extract consumption of product ethanol extract is consistent, but the hyperplasia of prostate inhibiting rate of high dose group is remote
Much larger than the summation of two single group hyperplasia of prostate inhibiting rates, synergy well is served, its experimental result is beyond expection.
Table 1：Impact of the male health-care product to BPH rat prostates volume and bulk index
Compare with model group：A p ＜ 0.05, aa p ＜ 0.01；Compare with Normal group：B p ＜ 0.05, bb p ＜
0.01；Compare c p ＜ 0.05, cc p ＜ 0.01 with testosterone enanthatas group；Compare with extract group：D p ＜ 0.05, dd p ＜
0.01。
Below the present invention disclosed with preferred embodiment, so it is not intended to limiting the invention, all employing equivalents
Or the technical scheme that equivalent transformation mode is obtained, it is within the scope of the present invention.
Claims (9)
1. a kind of health food for preventing and treating prostatitis and hyperplasia of prostate, it is characterised in that including the original of following parts by weight
Material：Lophatherum gracile 20-40 parts, maca 15-30 part, rhizoma zingiberis 10-20 parts, red sage root 5-15 parts, rhodiola root 5-15 parts, leek seed 5-10
Part.
2. health food according to claim 1, it is characterised in that the processing method of raw material is as follows：Above-mentioned raw materials are pressed
It is respectively processed according to ratio, cleans, dry or dry, crushes, you can；Or further with alcohol extracting or water extraction extraction.
3. health food according to claim 1, it is characterised in that the processing method of raw material is as follows：Lophatherum gracile, maca,
Rhizoma zingiberis, the red sage root are respectively adopted ethanol extraction, spray-dried that Herba Lophatheri extract, maca are extracted after the concentration of gained extract
Thing, Rhizoma Zingiberis extract and Salvia root P.E；Rhodiola root and leek seed are extracted using water, and after the concentration of gained extract, Jing sprayings are dry
It is dry to obtain gadol extract and Allium tubersum rottl extract.
4. health food according to claim 1, it is characterised in that the processing method of raw material is as follows：Above-mentioned raw materials are pressed
It is respectively processed according to ratio, lophatherum gracile, maca, rhizoma zingiberis, the red sage root, rhodiola root and leek seed are extracted respectively, concentrated, being dried
Herba Lophatheri extract, Maca extract, Rhizoma Zingiberis extract, Salvia root P.E, gadol extract and Allium tubersum rottl extract are obtained afterwards,
Then Herba Lophatheri extract, Maca extract, Rhizoma Zingiberis extract, Salvia root P.E, gadol extract and leek seed are extracted
Thing is sufficiently mixed uniformly, obtains final product traditional Chinese medicine extraction composition.
5. the health food according to any one of claim 1-4, it is characterised in that：The formulation of the health food is piece
Agent, granule, hard capsule or oral liquid.
6. health food according to claim 5, the preparation method of tablet is as follows：Traditional Chinese medicine extraction composition 30-60 parts, plus
Enter starch 20-40 parts, carboxymethylcellulose calcium 5-10 parts, dextrin 5-10 parts, add second at mixing 20-40 minutes in input mixer
Alcohol mixes 10-20 minutes as wetting agent, and mixed material is pelletized with 10-20 mesh sieves, is put in drying equipment and is dried, plus
Enter the magnesium stearate of 1-5 parts, whole grain, compressing tablet, packaging are obtained final product.
7. health food according to claim 5, the preparation method of granule is as follows：Traditional Chinese medicine extraction composition 30-70 parts,
Starch 10-25 parts, dextrin 10-30 parts, white granulated sugar 5-10 parts is added mixing 20-40 minutes in input mixer, to add ethanol to make
For wetting agent, mix 10-20 minutes, mixed material is pelletized with 10-20 mesh sieves, is put in drying equipment and is dried, dry
Grain is sieved with 20-60 eye mesh screens, removes coarse granule and fine powder, and packaging is obtained final product.
8. health food according to claim 5, the preparation method of hard capsule is as follows：Traditional Chinese medicine extraction composition 10-50
Part, starch 40-70 parts, dextrin 5-10 parts, add ethanol as wetting agent, mixing at mixing 20-30 minutes in input mixer
10-20 minutes, mixed material is pelletized with 10-20 mesh sieves, adds the hard fatty acids magnesium of 1-5 parts, whole grain, capsule charge, bag
Dress, obtains final product.
9. health food according to claim 5, the preparation method of oral liquid is as follows：1 part of traditional Chinese medicine extraction composition, adds
4-40 part purified waters are well mixed to obtain oral liquid, add appropriate D-araboascorbic acid sodium, filter, dispense, sterilize, pack, and obtain final product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611086042.7A CN106617053A (en) | 2016-12-01 | 2016-12-01 | Healthcare food for preventing and treating prostatitis and prostatic hyperplasia and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611086042.7A CN106617053A (en) | 2016-12-01 | 2016-12-01 | Healthcare food for preventing and treating prostatitis and prostatic hyperplasia and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106617053A true CN106617053A (en) | 2017-05-10 |
Family
ID=58814716
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611086042.7A Pending CN106617053A (en) | 2016-12-01 | 2016-12-01 | Healthcare food for preventing and treating prostatitis and prostatic hyperplasia and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106617053A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210052377A (en) * | 2019-10-31 | 2021-05-10 | (주)피에스에이 | Composition for the prevention or treatment of prostate-related disease comprising Rhodiola sachalinensis root extract containing kaempferol and epicatechin gallate |
| EP3838284A4 (en) * | 2019-10-31 | 2022-11-23 | Curome Biosciences Co., Ltd. | Composition, comprising salvia miltiorrhiza bunge extract as active ingredient, for prevention or treatment of benign prostatic hyperplasia or alopecia |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101019986A (en) * | 2007-03-16 | 2007-08-22 | 聂承和 | Health food for preventing and treating prostatosis and its prepn |
| CN103110704A (en) * | 2013-03-04 | 2013-05-22 | 湖南中医药大学 | Pharmaceutical composition for treating chronic prostatitis and preparation process |
| CN103859412A (en) * | 2014-04-02 | 2014-06-18 | 南京慧博生物科技有限公司 | Health-care food for male and preparation method thereof |
| CN103989753A (en) * | 2014-05-30 | 2014-08-20 | 李雪梅 | Medicinal composition for treating benign prostatic hyperplasia |
| CN104587256A (en) * | 2015-01-25 | 2015-05-06 | 董艳丽 | Traditional Chinese medicine composition for treating prostatitis |
| CN105831512A (en) * | 2015-01-13 | 2016-08-10 | 中国科学院昆明植物研究所 | Lepidium-meyenii-containing traditional Chinese medicine or food having tonification function without dryness, and preparation method and application of lepidium-meyenii-containing traditional Chinese medicine or food |
-
2016
- 2016-12-01 CN CN201611086042.7A patent/CN106617053A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101019986A (en) * | 2007-03-16 | 2007-08-22 | 聂承和 | Health food for preventing and treating prostatosis and its prepn |
| CN103110704A (en) * | 2013-03-04 | 2013-05-22 | 湖南中医药大学 | Pharmaceutical composition for treating chronic prostatitis and preparation process |
| CN103859412A (en) * | 2014-04-02 | 2014-06-18 | 南京慧博生物科技有限公司 | Health-care food for male and preparation method thereof |
| CN103989753A (en) * | 2014-05-30 | 2014-08-20 | 李雪梅 | Medicinal composition for treating benign prostatic hyperplasia |
| CN105831512A (en) * | 2015-01-13 | 2016-08-10 | 中国科学院昆明植物研究所 | Lepidium-meyenii-containing traditional Chinese medicine or food having tonification function without dryness, and preparation method and application of lepidium-meyenii-containing traditional Chinese medicine or food |
| CN104587256A (en) * | 2015-01-25 | 2015-05-06 | 董艳丽 | Traditional Chinese medicine composition for treating prostatitis |
Non-Patent Citations (5)
| Title |
|---|
| 吴大真等: "《现代名中医前列腺疾病治疗绝技》", 31 August 2011, 科学技术文献出版社 * |
| 孙纪更: "《一周学会中医自治前列腺病》", 31 May 2005, 华龄出版社 * |
| 曾庆明等: "《前列腺疾病中西医诊疗学》", 31 July 2002, 江西科学技术出版社 * |
| 贺菊乔等: "《中医外科特色疗法》", 30 April 2016, 山西科学技术出版社 * |
| 陈其华: "《前列腺炎：患者最想知道什么》", 28 February 2002, 山西科学技术出版社 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210052377A (en) * | 2019-10-31 | 2021-05-10 | (주)피에스에이 | Composition for the prevention or treatment of prostate-related disease comprising Rhodiola sachalinensis root extract containing kaempferol and epicatechin gallate |
| EP3838284A4 (en) * | 2019-10-31 | 2022-11-23 | Curome Biosciences Co., Ltd. | Composition, comprising salvia miltiorrhiza bunge extract as active ingredient, for prevention or treatment of benign prostatic hyperplasia or alopecia |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104147536B (en) | A kind of pharmaceutical composition treating hemorrhoid and preparation method thereof | |
| CN105213974A (en) | One treats lymphadenomatous Chinese medicine composition and application thereof | |
| CN106617053A (en) | Healthcare food for preventing and treating prostatitis and prostatic hyperplasia and preparation method thereof | |
| CN105325714A (en) | Compound feed for cows and preparation method thereof | |
| CN104173905B (en) | A kind of Chinese and Western medicine composite preparation for treating constipation and preparation method thereof | |
| CN102988747B (en) | Aristida triseta electuary for reducing hypertension, hyperglycemia and hyperlipidemia and preparation method thereof | |
| CN111481613A (en) | Application of Wubi yam pills in preparation of medicine for treating prostatic hyperplasia | |
| CN103028028B (en) | Traditional Chinese medicine agent for treating primary hepatic carcinoma | |
| CN103908616A (en) | Medicament for relieving radiation side reactions of cancer patients and preparation method thereof | |
| CN108324783A (en) | It is white to return ginseng Ling Donggan medicines for cancer | |
| CN103083459B (en) | Traditional Chinese medicinal compound preparation for treating constipation, and preparation method and application thereof | |
| CN103055271B (en) | Medicament for treating chronic gastritis and preparation method of medicament | |
| WO2022104712A1 (en) | Compound composition having effect of promoting bone health, preparation method therefor and application thereof | |
| CN101961481A (en) | Traditional Chinese medicine for treating liver-gallbladder qi stagnation type cholecystitis and preparation method thereof | |
| CN106729409A (en) | A kind of Chinese medicine composition for the nursing of children's indirect inguinal hernia | |
| CN103751675B (en) | Be used for the treatment of dyspeptic medicine of pig and preparation method thereof | |
| CN105012746A (en) | Pain-relieving capsule for treating migraine and preparation method of pain-relieving capsule | |
| CN105288274A (en) | Urination promoting and swelling diminishing preparation for treating nephrotic syndrome and preparation method | |
| CN102772585B (en) | Medicinal composition for treating appendicitis as well as preparation method and application thereof | |
| CN110522881A (en) | A kind of prevention and treatment lipoma Chinese medicine composition and preparation method thereof | |
| CN103690902A (en) | Traditional Chinese medicinal preparation for preventing radiation side reactions of nasopharynx cancer chemoradiotherapy | |
| CN109432343A (en) | It is a kind of to treat dyspeptic anaesthetic and its preparation process | |
| CN102198244B (en) | Medicament for treating gastric and duodenal ulcers, gastritis and other diseases and preparation method thereof | |
| CN110812405A (en) | Citrus aurantium flower essential oil for treating functional constipation | |
| CN108992655A (en) | A kind of anti-inflammatory is dispelled swollen Chinese medicine and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170510 |